Literature DB >> 32171427

Is HER2-positive metastatic breast cancer still an incurable disease?

Matteo Lambertini1, Ines Vaz-Luis2.   

Abstract

Entities:  

Year:  2020        PMID： 32171427     DOI： 10.1016/S1470-2045(20)30058-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer.

Authors:  Zachary Veitch; Domen Ribnikar; Derek Tilley; Patricia A Tang; Karen King; Philippe L Bedard; Sasha Lupichuk; David W Cescon
Journal:  Br J Cancer       Date:  2021-12-20       Impact factor: 9.075

Review 2.  Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.

Authors:  Paolo Tarantino; Stefania Morganti; Giuseppe Curigliano
Journal:  Explor Target Antitumor Ther       Date:  2021-04-30

3.  Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial.

Authors:  Matteo Lambertini; Dominique Agbor-Tarh; Otto Metzger-Filho; Noam F Ponde; Francesca Poggio; Florentine S Hilbers; Larissa A Korde; Saranya Chumsri; Olena Werner; Lucia Del Mastro; Rafael Caparica; Volker Moebus; Alvaro Moreno-Aspitia; Martine J Piccart; Evandro de Azambuja
Journal:  ESMO Open       Date:  2020-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.